Page last updated: 2024-12-06

zolmitriptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Zolmitriptan is a triptan medication used to treat migraine headaches. It is a selective serotonin 5-HT1B/1D receptor agonist, meaning it binds to and activates these receptors in the brain. This action helps to constrict blood vessels and reduce inflammation, both of which are believed to contribute to migraine pain. Zolmitriptan is typically taken orally as a tablet or nasal spray. It is also available as an injection for patients who do not respond to oral medications. Zolmitriptan is generally well-tolerated, but it can cause side effects such as dizziness, nausea, and fatigue. It is important to note that zolmitriptan should not be used by people with certain medical conditions, such as heart disease, high blood pressure, or a history of stroke. Research on zolmitriptan continues to explore its potential benefits and risks, as well as its effectiveness in treating various types of headache disorders. The compound's mechanism of action and its ability to target specific receptors in the brain make it a valuable tool for understanding migraine pathophysiology and developing new treatments for headache disorders.'

zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID60857
CHEMBL ID1185
CHEBI ID10124
SCHEMBL ID33336
MeSH IDM0237257

Synonyms (130)

Synonym
BIDD:GT0040
bdbm50033383
(s)-4-[3-(2-dimethylamino-ethyl)-1h-indol-5-ylmethyl]-oxazolidin-2-one
(s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)oxazolidin-2-one
AB00698244-05
gtpl60
ascotop
flezol
zomigon
bw-311c90
zolmitriptan rapidfilm
zolmitriptan [usan]
zomig nasal spray
zomig
4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-2-oxazolidinone
2-oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-, (s)-
(s)-4-((3-(2-(dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone
zomig-zmt
zomig zmt
c16h21n3o2
(s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-2-oxazolidinone
(s)-4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-2-oxazolidinone
MLS001424172
zolmitriptan
C07218
311c90
139264-17-8
smr000449310
MLS000758208
(s)-4-({3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}methyl)-1,3-oxazolidin-2-one
DB00315
4-[[3-(2-dimethylaminoethyl)-1h-indol-5-yl]methyl]oxazolidin-2-one
zolmitriptan (jan/usp/inn)
D00415
zomig (tn)
SPBIO_000656
SPECTRUM2_000728
SPECTRUM1505281
(4s)-4-({3-[2-(dimethylamino)ethyl]-1h-indol-5-yl}methyl)-1,3-oxazolidin-2-one
zipton
zolmitriptanum
zomigoro
zominat
CHEBI:10124 ,
HMS2093O14
HMS2052K17
(4s)-4-[[3-(2-dimethylaminoethyl)-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one
nsc-760383
CHEMBL1185 ,
cvt-427
311-c-90
HMS1922B04
nsc760383
pharmakon1600-01505281
dtxcid6025933
tox21_111455
dtxsid8045933 ,
cas-139264-17-8
zmt
zolmitriptane
HMS2235I22
CCG-38993
nsc 760383
unii-2fs66th3yw
rapimelt
2fs66th3yw ,
zolmitriptan [usan:inn:ban]
ascotopand
(4s)-4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl-2-oxazolidinone
NCGC00263884-03
S1649
AKOS015850706
zolmitriptan [mart.]
zolmitriptan [who-dd]
zolmitriptan [mi]
zolmitriptan [orange book]
(s)-4-[[3-[2-(dimethylamino)ethyl]indol-5-yl]methyl]-2-oxazolidinone
zolmitriptan [inn]
zolmitriptan [jan]
zolmitriptan [vandf]
zolmitriptan [ep monograph]
zolmitriptan [usp monograph]
zolmitriptan [usp-rs]
HY-B0229
NC00382
SCHEMBL33336
NCGC00263884-02
tox21_111455_1
KS-5072 ,
(s)-n,n-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1h -indol-3-yl]ethylamine
(s)-n,n-dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1h-indol-3-yl]ethylamine
(4s)-4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-2-oxazolidinone
(s) -n,n-dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1h -indol-3-yl]ethylamine
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
(4s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-2-oxazolidinone
Z0024
AB00698244_06
(4s)-4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-1,3-oxazolidin-2-one
SR-05000001693-1
sr-05000001693
zolmitriptan, united states pharmacopeia (usp) reference standard
zolmitriptan, >=98% (hplc)
J-007257
SBI-0206762.P001
139264-25-8
NCGC00263884-08
HMS3714H11
SW197762-2
(s)-4-{3-[2-(dimethylamino)ethyl]-1h-indol-5-ylmethyl}oxazolidin-2-one
bw-311c90;311c90
HB1801
(4s)-4-((3-(2-(dimethylamino)ethyl) -1h-indol-5-yl)methyl)-2-oxazolidinone
zolmitriptan (zomig)
Q218820
BCP10513
2-oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1h-indol-5-yl]methyl]-, (4s)-
HMS3884A06
EN300-18567396
BZ164590
zolmitriptan (mart.)
n02cc03
(4s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-1,3-oxazolidin-2-one
zolmitriptan (ep monograph)
4-((3-(2-dimethylaminoethyl)-1h-indol-5-yl)methyl)oxazolidin-2-one
(s)-4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-1,3-oxazolidin-2-one
zolmitriptan (usp-rs)
zolmitriptan (usp monograph)
2-oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1h-indol-5-yl)methyl)-,(s)-
zolmitriptan od
zolmiptriptan

Research Excerpts

Overview

Zolmitriptan is a widely used antimigraine drug. Its brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability.

ExcerptReferenceRelevance
"Zolmitriptan is a widely used antimigraine drug, and its brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability as compared to its oral drug delivery. "( Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive Nanoparticles for Intranasal Drug Delivery.
Jha, S; Mishra, D, 2022
)
2.43
"Zolmitriptan is an effective medicine used in the treatment of migraine."( Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method.
Bukka, R; Khezri, FANZ; Lakshmi, CSR; Nargund, SL; Nidhi, M, 2020
)
1.53
"Zolmitriptan (ZT) is a selective serotonin agonist that is used for the treatment of migraine. "( Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles - Formulation and Pharmacodynamic Assessment.
Awadeen, RH; Boughdady, MF; Meshali, MM, 2020
)
2.26
"Zolmitriptan (ZT) is a well-tolerated drug in migraine treatment suffering from low bioavailability due to low amount of the drug that reaches the brain after oral and nasal delivery. "( Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion.
Abdou, EM; Kandil, SM; Miniawy, HMFE, 2017
)
1.9
"Zolmitriptan is an abortive medication for migraine attacks, belonging to the triptan family."( Zolmitriptan for acute migraine attacks in adults.
Bird, S; Derry, S; Moore, RA, 2014
)
2.57
"Zolmitriptan is a potent second-generation triptan, prescribed for patients with migraine attacks, with or without an aura, and cluster headaches."( Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency.
Abd-Elal, RM; Bendas, ER; Rashed, HM; Shamma, RN, 2016
)
1.53
"Zolmitriptan is a selective 5-HT(1D) agonist."( Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study.
Avital, A; Gross-Isseroff, R; Hermesh, H; Shiloh, R; Stryjer, R; Weizman, A, 2009
)
2.52
"Zolmitriptan is a potent molecule for treatment of migraine. "( Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets.
Mahmoud, AA; Salah, S, 2012
)
2.05
"Zolmitriptan is a drug used in the acute treatment of migraine, which should not be used in high cardiovascular risk individuals because of its potential to induce vasospasm. "( [Myocardial infarction after taking zolmitriptan].
Batista, A; Carvalho, S; Ferreira, A; Ferreira, C; Linhares, F; Margato, R; Mateus, P; Moreira, I; Ribeiro, H, 2012
)
2.1
"Zolmitriptan is a 5HT(1B/1D) receptor agonist effective in the acute treatment of migraine. "( The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects.
Dane, A; Ikegami, A; Kemp, J; Nairn, K; Tateno, M; Yates, RA, 2002
)
2.01
"Zolmitriptan is a potent 5-HT(1B/1D) agonist whose targets include the peripheral and central components of the trigeminovascular system. "( Zolmitriptan: differences from sumatriptan.
Boes, CJ; Goadsby, PJ, 2001
)
3.2
"Zolmitriptan ODT is a convenient and beneficial alternative to conventional tablets and is preferred to sumatriptan conventional tablets by migraineurs."( Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet.
Charlesworth, BR; Dowson, AJ, 2003
)
1.33
"Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine. "( In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan.
Yao, TW; Yu, LS; Zeng, S, 2003
)
2.07
"Zolmitriptan is a widely available serotonin 5HT(1B/1D) receptor agonist with a long track record in clinical studies and in the treatment of acute migraine."( Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy.
Goadsby, PJ; Yates, R, 2006
)
2.5
"Zolmitriptan is a second-generation triptan developed for the treatment of migraine. "( Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Ashcroft, DM; Chen, LC, 2008
)
2.05
"Zolmitriptan 2.5 mg tablet is an effective treatment for acute attacks of migraine showing similar efficacy to almotriptan 12.5 mg, eletriptan 40 mg, and sumatriptan 50 mg, and being more effective than naratriptan 2.5 mg in terms of pain-free response at 2 hours post dose. "( Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Ashcroft, DM; Chen, LC, 2008
)
2.05
"Zolmitriptan is a well tolerated and effective acute migraine therapy providing rapid relief of migraine headache within 1 hour."( Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Adelman, JU; Earl, NL; Elkind, AH; Kudrow, DB; Mathew, NT; Ramadan, NM; Rapoport, AM, 1997
)
1.33
"Zolmitriptan is a newly developed 5HT1B/1D receptor agonist with both peripheral and central sites of action in the trigeminovascular system due to greater lipophilicity relative to the more hydrophilic antimigraine compound sumatriptan."( Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
Goadsby, PJ; Hoskin, KL, 1998
)
1.02
"Zolmitriptan is a selective 5HT1B/1D-agonist for the treatment of migraine. "( The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Dixon, RM; Jackson, SH; Layton, GR; Peck, RW; Posner, J; Rolan, PE; Seaber, EJ; Weatherley, BC, 1998
)
1.98
"Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy. "( Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Cleary, EW; Dilzer, SC; Huffman, CS; Lasseter, KC; Smith, DA; Watkins, S, 1998
)
2.01
"Zolmitriptan (Zomig) is a 5HT1B/1D agonist which has the ability to cross the intact blood-brain barrier to access central as well as peripheral receptors. "( Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers.
Dixon, R; Hughes, AM; Kemp, JV; Nairn, K; Sellers, M; Yates, RA, 1998
)
2.02
"Zolmitriptan is a new serotonergic agonist with excellent oral bioavailability exhibiting a potent symptomatic antimigraine effect. "( [Mechanism of action of zolmitriptan].
Pascual, J, 1998
)
2.05
"*Zolmitriptan (Zomig) is an antimigraine drug similar to sumatriptan.*The clinical file mainly comprises placebo-controlled, dose-finding studies recommending an optimal oral dose of 2.5 mg.*Zolmitriptan has been compared with sumatriptan in a trial that showed no difference in efficacy. "( Zolmitriptan.
, 1999
)
2.66
"Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist ('triptan'). "( Zolmitriptan: a review of its use in migraine.
Gunasekara, NS; Hills, C; Spencer, CM, 1999
)
3.19
"Zolmitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine. "( Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.
Farkkila, M; Hering-Hanit, R; Mauskop, A; Rapoport, A; Warner, J, 1999
)
3.19
"Zolmitriptan is an anti-migraine agent with action at 5-HT1B/D receptors. "( Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.
de Almeida, RM; Faccidomo, S; Fish, EW; Miczek, KA; Nikulina, EM, 2001
)
3.2
"Zolmitriptan proved to be an effective and behaviorally specific anti-aggressive agent in situations that engender moderate and alcohol-heightened levels of aggression. "( Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.
de Almeida, RM; Faccidomo, S; Fish, EW; Miczek, KA; Nikulina, EM, 2001
)
3.2

Effects

Oral zolmitriptan 2.5 and 5mg has a rapid onset of action (significant headache relief is observed at 45 minutes) and efficacy is sustained in most patients who respond at 2 hours.

Zolmitriptan has been considered effective treatment in the acute phase of migraine, menstrual-related migraine and cluster headache attacks. The drug rapidly dissolves on the tongue and can be taken quickly, conveniently and discreetly without fluid intake.

ExcerptReferenceRelevance
"Zolmitriptan nasal spray has a rapid onset of action and high efficacy."( The evolving management of migraine.
Ashkenazi, A; Silberstein, SD, 2003
)
1.04
"Oral zolmitriptan 2.5 and 5mg has a rapid onset of action (significant headache relief is observed at 45 minutes) and efficacy is sustained in most patients who respond at 2 hours."( Zolmitriptan: a review of its use in migraine.
Gunasekara, NS; Hills, C; Spencer, CM, 1999
)
2.2
"Zolmitriptan has been considered effective treatment in the acute phase of migraine, menstrual-related migraine and cluster headache attacks. "( Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines.
Casolla, B; D'Alonzo, L; Lionetto, L; Martelletti, P; Mastropietri, F; Negro, A; Simmaco, M, 2012
)
2.11
"Zolmitriptan nasal spray has a rapid onset of action and high efficacy."( The evolving management of migraine.
Ashkenazi, A; Silberstein, SD, 2003
)
1.04
"Zolmitriptan nasal spray has been shown to be fast acting and highly effective in the treatment of migraine, as assessed using standard endpoints, such as headache response and pain-free rates."( Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Aschoff, J; Charlesworth, BR; Gawel, M; May, A, 2005
)
3.21
"Zolmitriptan has been available as a conventional oral tablet for more than seven years, and is established as a highly effective, well-tolerated compound for the acute treatment of migraine."( Part III: the convenience of, and patient preference for, zolmitriptan orally disintegrating tablet.
Almqvist, P; Dowson, AJ, 2005
)
1.29
"Zolmitriptan has been developed in an orally disintegrating tablet (ODT) formulation that rapidly dissolves on the tongue and can be taken quickly, conveniently and discreetly without fluid intake. "( Part IV: effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: a post-marketing surveillance study in Germany.
Diener, HC; Gendolla, A, 2005
)
2.09
"Zolmitriptan has suitable bioavailability for an acute oral migraine treatment and there are no significant unidentified metabolites in man."( The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Chittick, G; Dixon, RM; Gibbens, M; Leavens, WJ; Liptrot, J; On, N; Pack, RW; Posner, J; Rolan, PE; Seaber, E, 1997
)
1.24
"Zolmitriptan has vasoconstrictor activity in cerebral vessels and may cause slight elevations of blood pressure in subjects without hypertension."( Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Cleary, EW; Dilzer, SC; Huffman, CS; Lasseter, KC; Smith, DA; Watkins, S, 1998
)
1.29
"Oral zolmitriptan 2.5 and 5mg has a rapid onset of action (significant headache relief is observed at 45 minutes) and efficacy is sustained in most patients who respond at 2 hours."( Zolmitriptan: a review of its use in migraine.
Gunasekara, NS; Hills, C; Spencer, CM, 1999
)
2.2
"Zolmitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache."( Review of zolmitriptan and its clinical applications in migraine.
Charlesworth, B; Dowson, AJ, 2002
)
1.44

Actions

ExcerptReferenceRelevance
"Zolmitriptan may cause myocardial infarction (MI) even in the absence of significant coronary artery disease."( Myocardial infarction after taking zolmitriptan.
Galbut, BH; Galbut, EJ; Kavinsky, CJ; McMullan, PW; Pacheco-Coronado, R; Schaer, GL; Snell, J, 2005
)
1.33

Treatment

Treatment with zolmitriptan nasal spray, compared with placebo, also produced a higher headache response rate from 10 minutes post-dose (15.1% vs. 13.9%) Treatment was well tolerated.

ExcerptReferenceRelevance
"Pre-treatment with zolmitriptan also significantly reduces the expression of light-induced c-fos in the SCN."( Triptans attenuate circadian responses to light.
Antle, MC; Baskerville, JD; Basu, P; Ie, N; Smith, VM; Wensel, AL, 2015
)
0.74
"Treatment with zolmitriptan nasal spray, compared with placebo, also produced a higher headache response rate from 10 minutes post-dose (15.1% vs."( Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Aschoff, J; Charlesworth, BR; Gawel, M; May, A, 2005
)
2.11
"Treatment with zolmitriptan nasal spray was well tolerated."( Efficacy of zolmitriptan nasal spray in adolescent migraine.
Hershey, AD; Lewis, DW; Wasiewski, WW; Winner, P, 2007
)
1.06

Toxicity

ExcerptReferenceRelevance
" Adverse experiences reported are generally dose related, mild to moderate and resolve spontaneously."( Clinical safety of 311C90: aggregated data from patients and volunteers to date.
Earl, NL, 1996
)
0.29
" Safety assessments include electrocardiograms, the frequency, intensity and duration of adverse experiences, and routine haematology, urinalysis and clinical chemistry measures."( Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
Geraud, GE, 1996
)
0.29
" The most frequent adverse effects were nausea and dizziness."( [Safety profile of 311C90 (zolmitriptan)].
Morales Asín, F, 1998
)
0.6
" Overall, adverse events occurred in 32."( Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
Charlesworth, BR; Diener, HC; Dowson, AJ; Färkkilä, M; Gawel, M; Green, J; Hansen, SB, 2005
)
1.77
" Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire."( Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
Assaid, C; Dodick, DW; Ho, TW; Kost, J; Lines, C, 2011
)
0.56
" Endpoints were 2-24-hour sustained pain freedom and no adverse events from 0-24 hours (SPF24NAE), 2-24 hour sustained pain relief and no adverse events from 0-24 hours (SPR24NAE), pain freedom at 2 hours and no adverse events from 0-24 hours (PF2NAE), and pain relief at 2 hours and no adverse events from 0-24 hours (PR2NAE)."( Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
Assaid, C; Dodick, DW; Ho, TW; Kost, J; Lines, C, 2011
)
0.56
" Systemic adverse events were consistent with previous triptan trials, and included dizziness, paresthesia, muscle tightness, and nausea, all of which occurred in < 5% of patients in any group."( Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
Brandes, JL; Kellerman, DJ; Kudrow, DB; Schmidt, PC; Spierings, EL; Tepper, SJ; Weintraub, J, 2018
)
0.69
" Most participants (96%) experienced at least 1 adverse event, the vast majority of which concerned the application site, and > 95% of which were mild."( Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine.
Elbuluk, N; Foreman, PK; Friedman, DI; Hindiyeh, N; Kellerman, DJ; Nahas, SJ; Schmidt, P, 2021
)
0.86
"The majority of participants experienced cutaneous adverse reactions such as application site erythema, swelling, and bleeding, and most reactions were scored as mild."( Long term safety, tolerability, and efficacy of intracutaneous zolmitriptan (M207) in the acute treatment of migraine.
Elbuluk, N; Foreman, PK; Friedman, DI; Hindiyeh, N; Kellerman, DJ; Nahas, SJ; Schmidt, P, 2021
)
0.86
" There were few treatment-related adverse events and none led to discontinuation."( A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
McVige, J; Visser, H; Yonker, ME; Zeitlin, L, 2022
)
0.93
" ZNS was safe and well tolerated in this pediatric population."( A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
McVige, J; Visser, H; Yonker, ME; Zeitlin, L, 2022
)
0.93
" The primary efficacy endpoint was pain freedom at 2 h, and the primary safety endpoint was adverse events (AEs)."( Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Duan, S; Li, G; Liu, L; Liu, Z; Ren, Z; Wang, Z; Xia, H; Zhu, T, 2023
)
0.91
" Zavegepant nasal spray 10 mg had the fewest adverse side effects."( Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Duan, S; Li, G; Liu, L; Liu, Z; Ren, Z; Wang, Z; Xia, H; Zhu, T, 2023
)
0.91

Pharmacokinetics

The nasal spray was prepared from Zolmitriptan loaded chitosan nanoparticles and evaluated for pharmacokinetic properties. Blood pressure, heart rate, ECG, and central nervous system effects were monitored. The area under the curve (AUC) and highest observed plasma concentration (Cmax) of zolmitripan were similar in both age groups.

ExcerptReferenceRelevance
" The pharmacokinetic and tolerability profiles of single oral doses from 1-50 mg 311C90 were investigated in 12 healthy male volunteers in a double-blind, placebo-controlled, dose-escalating study."( The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers.
Churchus, R; On, N; Phillips, S; Posner, J; Rolan, P; Seaber, E, 1996
)
0.29
" There was no evidence of significant changes in the pharmacokinetic parameters of zomitriptan or its metabolites after the last dose compared to the first, except for an expected rise in peak concentrations and a small, apparent increase in the amount of drug excreted in urine and hence in CLR."( The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Dixon, R; Gibbens, M; Gillotin, C; Peck, RW; Posner, J, 1997
)
0.51
" Pharmacodynamic measures included oscillometric blood pressure, systolic blood pressure at the toe and arm using a strain gauge technique, stroke volume and cardiac output using bioimpedance cardiography, high-resolution ultrasound to measure brachial arterial diameter and a novel Doppler method to measure blood flow velocity."( Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
Dixon, RM; Evans, DH; Meire, HB; On, N; Posner, J; Rolan, PE; Watt, H, 1997
)
0.52
" On average, 75% of its eventual Cmax is achieved within 1 h of dosing."( The clinical pharmacokinetics of zolmitriptan.
Dixon, R; Warrander, A, 1997
)
0.58
" Blood pressure, heart rate, ECG, and central nervous system effects were monitored, and pharmacokinetic parameters of zolmitriptan and its metabolites calculated."( The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Dixon, RM; Jackson, SH; Layton, GR; Peck, RW; Posner, J; Rolan, PE; Seaber, EJ; Weatherley, BC, 1998
)
0.75
" Zolmitriptan plasma concentrations were higher in women than in men, with higher values of AUC and Cmax and lower total clearance in women."( Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Cleary, EW; Dilzer, SC; Huffman, CS; Lasseter, KC; Smith, DA; Watkins, S, 1998
)
1.48
" The metabolism of zolmitriptan was reduced in patients with severe hepatic impairment compared with healthy subjects, resulting in higher peak plasma concentrations (47%), increased exposure (226%), and prolonged half-life (157%)."( Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
Delvaux, M; Dixon, R; French, S; Kemp, J; Leclerc, V; Rautureau, J; Sellers, M, 1998
)
0.87
" Cmax and AUC of oral zolmitriptan were dose-proportional and there was a 13 and 16% fall in mean zolmitriptan Cmax and AUC, respectively, when administered after food."( The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
Allanson, J; Hefting, NR; Jonkman, JH; Peck, RW; Seaber, EJ; Smith, DA; Sollie, FA; van Lier, JJ; Wemer, J, 1998
)
0.84
" Plasma levels were maintained at a plateau between 1 and 6 hours postdose, then decreased with a half-life of approximately 3 hours."( Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers.
Dixon, R; Nairn, K; Seaber, E; Yates, R, 2002
)
0.55
" The comparison of pharmacokinetic and clinical data available from different formulations of zolmitriptan contributes both to the understanding of its mode of action and the characteristics required of an acute migraine treatment if it is to meet patient needs."( Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy.
Goadsby, PJ; Yates, R, 2006
)
2
" The method was successfully applied to a pharmacokinetic study of zolmitriptan after an oral administration of 5 mg zolmitriptan to 20 healthy volunteers."( Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study.
Chen, X; Jin, F; Liu, D; Luan, Y; Zhong, D, 2006
)
0.91
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic parameters may vary as a consequence of gender differences, inter- and intra-subjects variability and delivery system."( Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines.
Casolla, B; D'Alonzo, L; Lionetto, L; Martelletti, P; Mastropietri, F; Negro, A; Simmaco, M, 2012
)
0.66
"Limited pharmacokinetic sampling strategy may be useful for predicting the area under the curve (AUC) for triptans and may have clinical utility as a prospective tool for prediction."( Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application.
Srinivas, NR; Syed, M, 2016
)
0.67
" The nasal spray was prepared from Zolmitriptan loaded chitosan nanoparticles and evaluated for pharmacokinetic properties."( Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method.
Bukka, R; Khezri, FANZ; Lakshmi, CSR; Nargund, SL; Nidhi, M, 2020
)
1.09
" The incorporation of the NLCs in in situ gelling hard gelatin capsules fulfilled a dual function in increasing permeability, as well as sustaining the pharmacodynamic effect."( Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles - Formulation and Pharmacodynamic Assessment.
Awadeen, RH; Boughdady, MF; Meshali, MM, 2020
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
" Zolmitriptan, at eight times the likely therapeutic dose, was generally well tolerated both alone and in combination with ergotamine."( Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers.
Dixon, RM; Evans, DH; Meire, HB; On, N; Posner, J; Rolan, PE; Watt, H, 1997
)
1.43

Bioavailability

Zolmitriptan is a widely used antimigraine drug. Brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability.

ExcerptReferenceRelevance
" It is rapidly absorbed, with 75% of maximal plasma concentration (Cmax) attained within 1 hour and good absolute oral bioavailability (approximately 40%)."( 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
Ferrari, MD, 1997
)
0.3
"Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of zolmitriptan (311C90), a novel 5HT1D agonist for the acute treatment of migraine."( The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Chittick, G; Dixon, RM; Gibbens, M; Leavens, WJ; Liptrot, J; On, N; Pack, RW; Posner, J; Rolan, PE; Seaber, E, 1997
)
0.72
" Zolmitriptan has suitable bioavailability for an acute oral migraine treatment and there are no significant unidentified metabolites in man."( The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
Chittick, G; Dixon, RM; Gibbens, M; Leavens, WJ; Liptrot, J; On, N; Pack, RW; Posner, J; Rolan, PE; Seaber, E, 1997
)
1.43
" In healthy volunteers it is rapidly and extensively absorbed and has favorable oral bioavailability (approximately 40%) which is not affected by concomitant food intake."( The clinical pharmacokinetics of zolmitriptan.
Dixon, R; Warrander, A, 1997
)
0.58
"Concomitant administration of zolmitriptan and paracetamol resulted in a slight increase in bioavailability of zolmitriptan and a reduced rate and extent of paracetamol absorption."( The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
Layton, G; Peck, RW; Posner, J; Ridout, G; Seaber, EJ, 1997
)
0.87
"At therapeutic doses zolmitriptan has good oral bioavailability in healthy volunteers and has dose-proportional pharmacokinetics that are not affected by food to any clinically relevant extent."( The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
Allanson, J; Hefting, NR; Jonkman, JH; Peck, RW; Seaber, EJ; Smith, DA; Sollie, FA; van Lier, JJ; Wemer, J, 1998
)
0.85
"Zolmitriptan is a new serotonergic agonist with excellent oral bioavailability exhibiting a potent symptomatic antimigraine effect."( [Mechanism of action of zolmitriptan].
Pascual, J, 1998
)
2.05
"Zolmitriptan (previously known as 311C90) is a serotoninergic 5-HT1B/D agonist with high oral bioavailability with a double, central and peripheral, action mechanism."( [Clinical efficacy of zolmitriptan in migraine].
Leira, R; Noya, M, 1998
)
2.06
" Zolmitriptan introduced in 1994 is an agonists of 5-HT 1B/1D receptor, is active both peripherally and centrally, is well absorbed from the digestive tract and has a good bioavailability index /40%/."( [Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor].
Prusiński, A, 1999
)
1.21
" A qualitative model for pharmacokinetic properties was then used to guide the synthesis toward molecules likely to have oral bioavailability in humans."( Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
Barrett, V; Brockwell, M; Cambridge, D; Farrant, DR; Foster, C; Giles, H; Glen, RC; Hill, AP; Hobbs, H; Honey, A; Jandu, KS; Martin, GR; Salmon, J; Selwood, DL; Smith, D; Woollard, P, 2001
)
0.31
" Also, some nasal preparations have significant adverse effects or are not well absorbed and therefore do not work consistently; others are more challenging to administer as a result of their delivery apparatus."( Intranasal medications for the treatment of migraine and cluster headache.
Bigal, ME; Rapoport, AM; Sheftell, FD; Tepper, SJ, 2004
)
0.32
" The proposed method enables the unambiguous identification and quantification of zolmitriptan for pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of zolmitriptan in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry.
Li, W; Mao, G; Tian, Y; Xu, F; Zhang, Z, 2004
)
0.88
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor."( Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Assaid, C; Dodick, DW; Fan, X; Ferrari, MD; Froman, S; Galet, V; Ho, TW; Koppen, H; Kost, J; Leibensperger, H; Lines, C; Winner, PK, 2008
)
0.55
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Its current oral therapies present drawbacks such as slow onset of action, low bioavailability and large inter-subject variability."( Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets.
Mahmoud, AA; Salah, S, 2012
)
0.61
" In this study, we formulate a Zolmitriptan (ZT) & ketorolac tromethamine (KT) loaded thermo reversible in-situ mucoadhesive intranasal gel (TMISG) formulation which gels at the nasal mucosal temperature and contains a bioadhesive polymer (Xyloglucan) that lengthens the residence time will enhance the bioavailability of the combinational drugs."( Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design.
Garg, T; Goyal, AK; Kumar, A; Rath, G; Sarma, GS, 2015
)
0.7
" The results revealed that the absolute bioavailability was about 63%."( Drug in Adhesive Patch of Zolmitriptan: Formulation and In vitro /In vivo Correlation.
Fang, L; Liu, C, 2015
)
0.72
"Zolmitriptan is the drug of choice for migraine, but low oral bioavailability (<50%) and recurrence of migraine lead to frequent dosing and increase in associated side effects."( Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies.
Dhamecha, D; Jalalpure, S; Shahi, S; Shelke, S, 2016
)
2.12
" The absolute bioavailability of zolmitriptan is about 40% for oral administration; due to hepatic first metabolism."( Trans-nasal zolmitriptan novasomes: in-vitro preparation, optimization and in-vivo evaluation of brain targeting efficiency.
Abd-Elal, RM; Bendas, ER; Rashed, HM; Shamma, RN, 2016
)
1.09
"Zolmitriptan (ZT) is a well-tolerated drug in migraine treatment suffering from low bioavailability due to low amount of the drug that reaches the brain after oral and nasal delivery."( Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion.
Abdou, EM; Kandil, SM; Miniawy, HMFE, 2017
)
1.9
"The aim was to prepare an optimized zolmitriptan (ZT)-loaded transfersome formulation using Box-Behnken design for improving the bioavailability by nasal route for quick relief of migraine and further to compare with a marketed nasal spray."( Development of zolmitriptan transfersomes by Box-Behnken design for nasal delivery: in vitro and in vivo evaluation.
Dudhipala, N; Narala, A; Pitta, SK; Veerabrahma, K, 2018
)
1.11
"9-mg zolmitriptan was delivered with high efficiency (85%) and high absolute bioavailability (77%)."( Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray.
Ameri, M; Diep, AN; Hochart, G; Lewis, H; Nguyen, J; Queja, A, 2018
)
1.24
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Zolmitriptan is a widely used antimigraine drug, and its brain targeting by nasal route in the form of mucoadhesive nanoparticles is more effective in migraine treatment as it provides fast relief and good bioavailability as compared to its oral drug delivery."( Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive Nanoparticles for Intranasal Drug Delivery.
Jha, S; Mishra, D, 2022
)
2.43

Dosage Studied

Zolmitriptan nasal spray was superior to placebo as early as 15 minutes after dosing. It is unlikely that the pharmacokinetic changes will lead to clinically important changes in pharmacological effects.

ExcerptRelevanceReference
" The adverse experience and efficacy profile appears to be consistent with previous 311C90 studies and this dosing regimen of 311C90 was well tolerated during multiple exposures."( Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine.
Geraud, GE, 1996
)
0.29
" The dosing regimen was well tolerated during multiple exposures."( 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
Zagami, AS, 1997
)
0.3
" After the last 10 mg dose, mean dosing interval zolmitriptan AUC was 80."( The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
Dixon, R; Gibbens, M; Gillotin, C; Peck, RW; Posner, J, 1997
)
0.77
" Plasma concentrations are sustained for 4 to 6 h after dosing with single or multiple peaks in the plasma concentration-time profile, reflecting continued absorption down the gastrointestinal tract."( The clinical pharmacokinetics of zolmitriptan.
Dixon, R; Warrander, A, 1997
)
0.58
"5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%)."( Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
Sawyer, J; Schoenen, J, 1997
)
1.74
" It is therefore unlikely that the pharmacokinetic changes will lead to clinically important changes in pharmacological effects and dosage adjustment of zolmitriptan is not required in patients taking propranolol for migraine prophylaxis."( The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
Dixon, R; Gillotin, CG; Layton, G; Peck, RW; Posner, J; Seaber, EJ; Weatherley, BC, 1997
)
0.73
" In young subjects, concentrations were higher in women than in men, but the differences were insufficient to justify dosage adjustment."( The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Dixon, RM; Jackson, SH; Layton, GR; Peck, RW; Posner, J; Rolan, PE; Seaber, EJ; Weatherley, BC, 1998
)
0.54
" Patients with moderate hepatic impairment require no dosage adjustment, but the recommended daily intake of zolmitriptan may need to be reduced in patients with severe hepatic impairment."( Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
Delvaux, M; Dixon, R; French, S; Kemp, J; Leclerc, V; Rautureau, J; Sellers, M, 1998
)
0.76
" Headache response rates and pain-free response rates were assessed within two hours of dosing with zolmitriptan, and response rates were compared across migraines with and without a history of aura, and associated or not with menses."( Zolmitriptan provides consistent migraine relief when used in the long-term.
Edvinsson, L; Geraud, G; Korczyn, A; Mauskop, A; Pfaffenrath, V; Tuchman, M, 1999
)
1.96
"This phase II study investigated the efficacy, tolerability and dose-response relationship of oral zolmitriptan in the treatment of a single migraine attack in Japanese patients."( Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study.
Fukuuchi, Y; Itoyama, Y; Iwata, M; Morimatsu, M; Nakashima, K; Sakai, F; Sobue, G; Tashiro, K; Tsuji, S, 2002
)
1.97
"In direct head-to-head comparative clinical trials, oral rizatriptan 10 mg enabled more migraine sufferers to function normally at 2 h after dosing than oral sumatriptan, naratriptan, and zolmitriptan."( Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials.
Bussone, G; D'Amico, D; Gerth, W; Lines, CR; McCarroll, KA, 2002
)
0.51
" The objective of phase two was to investigate patients' dosing patterns, satisfaction and preference following open-label treatment with the nasal spray."( Treatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study.
Aschoff, J; Charlesworth, BR; Gawel, M; May, A, 2005
)
0.62
" Recurrence rates 2-24 h after dosing were 32."( Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
Acuto, G; Allais, G; Benedetto, C; Bussone, G; Cabarrocas, X; Esbri, R, 2006
)
0.59
" The proposed methods have been applied successfully for the analysis of the drug in its dosage forms."( Extractive spectrophotometric methods for determination of zolmitriptan in tablets.
Aydogmus, Z; Inanli, I,
)
0.37
" Extrapolation of these results to humans suggests the feasibility of delivering therapeutic amounts of zolmitriptan at faster rates than those from existing dosage forms."( Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo.
Kalia, YN; Patel, SR; Sharma, A; Zhong, H, 2009
)
0.81
"8 g/kg in a within-subject, counterbalanced dosing design."( Zolmitriptan and human aggression: interaction with alcohol.
Gowin, JL; Lane, SD; Moeller, FG; Swann, AC, 2010
)
1.8
"A 5-mg dose of zolmitriptan effectively reduced alcohol-related aggression in an acute dosing protocol, demonstrating an interaction of 5-HT and alcohol in human aggressive behavior."( Zolmitriptan and human aggression: interaction with alcohol.
Gowin, JL; Lane, SD; Moeller, FG; Swann, AC, 2010
)
2.16
" No electroactive interferences from the excipients and endegenous substances were found in the pharmaceutical dosage form and the biological sample, respectively."( Anodic voltammetry of zolmitriptan at boron-doped diamond electrode and its analytical applications.
Canbaz, D; Uslu, B, 2010
)
0.68
" These results demonstrated that the submicron emulsion preparation of ZT was a relatively safe dosage form for rapid and effective intranasal delivery of ZT."( Preparation and evaluation of zolmitriptan submicron emulsion for rapid and effective nasal absorption in beagle dogs.
Cai, C; Gu, P; He, H; Qi, N; Tang, X; Yu, C; Zhang, W, 2011
)
0.66
" All of the five subjects who were examined 1 week after dosing with zolmitriptan showed higher BP ND post drug administration compared with baseline."( A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers.
Farde, L; Halldin, C; Jučaite, A; Kanes, S; McCarthy, DJ; Nord, M; Stenkrona, P; Varnäs, K, 2013
)
0.85
"This work describes a simple and sensitive method for simultaneous determination of zolmitriptan, naproxen and propranolol in their dosage forms using HPLC."( A rapid and sensitive HPLC assay of some concomitant anti-migraine drugs.
El-Kadi, AO; Lotfy, HM; Michael, AM; Rezk, MR; Shehata, MA, 2014
)
0.63
"Bioadhesive nasal dosage forms are an attractive method for overcoming rapid mucociliary clearance transport in the nose and for delivering the drug directly to brain."( Formulation and evaluation of chitosan-chondroitin sulphate based nasal inserts for zolmitriptan.
Kaur, G; Kaur, K, 2013
)
0.61
" A microemulsion-based technology has various advantages over other technically complex dosage forms."( Duel-acting subcutaneous microemulsion formulation for improved migraine treatment with zolmitriptan and diclofenac: formulation and in vitro-in vivo characterization.
Christie, M; Dubey, R; Martini, LG, 2014
)
0.62
"Zolmitriptan is the drug of choice for migraine, but low oral bioavailability (<50%) and recurrence of migraine lead to frequent dosing and increase in associated side effects."( Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies.
Dhamecha, D; Jalalpure, S; Shahi, S; Shelke, S, 2016
)
2.12
"The inverted U-shaped, methamphetamine dose-response function for intake on the fixed ratio 5 schedule was shifted downward by CP 94,253 both before and after abstinence."( Preclinical Evidence That 5-HT1B Receptor Agonists Show Promise as Medications for Psychostimulant Use Disorders.
Cotter, AR; Garcia, R; Leslie, K; Neisewander, JL; Olive, MF, 2017
)
0.46
" Randomized controlled trials (RCTs) using intranasal agents (no restrictions on dose, formulation, dosing regimen or timing of the first dose) to treat adult patients with acute migraine were included."( Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Duan, S; Li, G; Liu, L; Liu, Z; Ren, Z; Wang, Z; Xia, H; Zhu, T, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
vasoconstrictor agentDrug used to cause constriction of the blood vessels.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tryptaminesTryptamine and its substitution derivatives.
oxazolidinoneAn oxazolidine containing one or more oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00400.003245.467312,589.2998AID2517
GALC proteinHomo sapiens (human)Potency4.466828.183828.183828.1838AID1159614
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.60320.001022.650876.6163AID1224838
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.10130.00010.532610.0000AID3849; AID3860
5-hydroxytryptamine receptor 1DHomo sapiens (human)IC50 (µMol)0.00280.00050.28702.4000AID4642
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.00190.00010.808710.0000AID4626; AID4908; AID4934
5-hydroxytryptamine receptor 1BHomo sapiens (human)IC50 (µMol)0.00620.00050.39756.5000AID4270
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki0.00420.00010.54859.2100AID4255
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd0.00700.00020.62779.3325AID36944
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd0.00700.00020.62779.3325AID36944
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd0.00700.00020.62779.3325AID36944
5-hydroxytryptamine receptor 1BHomo sapiens (human)EC50 (µMol)0.01570.01160.13880.4300AID4496
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (78)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (172)

Assay IDTitleYearJournalArticle
AID3860Binding affinity for cloned human 5-hydroxytryptamine 1A receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID141603Binding affinity against Muscarinic acetylcholine receptor M3 using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID42945-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID1918193Dissociation constant, pKa of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID673053Cardiovascular toxicity in human coronary arteries assessed as induction of vasoconstriction after 30 mins2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID5451Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1180729Antimigraine activity in migraine patient assessed as pain freedom incidence at 5 mg after 2 hrs (Rvb = 9.6%)2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1764400Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID44855-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID4934Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID3984Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID165752The compound was tested for functional activity by measuring the contraction of saphenous vein from New Zealand white rabbit1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID41902Binding affinity towards Beta adrenergic receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID88481Binding affinity against H2 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID3658Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID4496Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID4912Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID61355Binding affinity against dopamine receptor D1 in rat striatum using [3H]SCH-23390 as radioligand1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID4270Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1180732Antimigraine activity in migraine patient assessed as pain relief incidence at 5 mg after 2 hrs (Rvb = 27.7%)2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID4923Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4908Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1918194Lipophilicity, log D of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID4255In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID1180708Antimigraine activity in migraine patient assessed as induction pain relief at 5 mg after 2 hrs2014Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID4869The compound was tested for binding affinity against 5-HT1D receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID3789Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID61073Binding affinity against Dopamine receptor D2 using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID4894Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID63361Binding affinity was evaluated by Dopamine receptor D1 agonism in the calf striatum by displacing SCH 233901995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID64787Binding affinity against Dopamine receptor D2 in rat striatum using [3H]-spiperone as radioligand1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID4868Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1764398Substrate activity at P-gp (unknown origin) assessed as net efflux ratio2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID732420Efflux ratio of permeability from basolateral to apical side over apical to basolateral in pig LLC-PK1 cells overexpressing human MDR1 relative to efflux ratio in parental cell line2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
AID1864498Substrate activity at human OCT3 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID4626In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID3661Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1764402Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1864507Substrate activity at OCT1 (unknown origin) assessed as uptake ratio2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID74051Ability to inhibit [125I]- albumin extravasation into dura following electrical stimulation of trigeminal ganglion of Guinea pig2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1764399Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID4642Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID3659Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID5452The compound was tested for binding affinity against 5-HT2A receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1864493Substrate activity at human OCT3 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1764401Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Development of an
AID87378Binding affinity against H1 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID673054Cardiovascular toxicity in human coronary arteries assessed as induction of vasoconstriction after 30 mins relative to serotonin2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
The synthesis and SAR of calcitonin gene-related peptide (CGRP) receptor antagonists derived from tyrosine surrogates. Part 1.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1864506Substrate activity at human OCT2 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID166852Relative binding affinity in rabbit saphenous vein functional assay compared to 5-HT2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID6037Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID36944Binding affinity against Alpha-2 adrenergic receptor in rat cortex using [3H]-idazoxan as radioligand1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36415Binding affinity against Alpha-1 adrenergic receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID165751Maximum vein contraction obtained relative to 5-hydroxytryptamine1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID4941Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID4867The compound was tested for intrinsic activity against 5-HT1D receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID36519Binding affinity against Alpha-2 adrenergic receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID142790Binding affinity against Muscarinic acetylcholine receptor M2 using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID4751Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID6218Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID3849In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand1998Bioorganic & medicinal chemistry letters, Mar-17, Volume: 8, Issue:6
Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist.
AID3660Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29656Oral bioavailability in human2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)2005Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F2005Naunyn-Schmiedeberg's archives of pharmacology, Mar, Volume: 371, Issue:3
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1999European journal of pharmacology, Mar-05, Volume: 368, Issue:2-3
Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (445)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's97 (21.80)18.2507
2000's206 (46.29)29.6817
2010's112 (25.17)24.3611
2020's30 (6.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.69 (24.57)
Research Supply Index6.36 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index153.08 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (84.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials113 (24.41%)5.53%
Reviews86 (18.57%)6.00%
Case Studies32 (6.91%)4.05%
Observational1 (0.22%)0.25%
Other231 (49.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Open-label 4-way Crossover Study to Compare the PK, Safety, and Tolerability of M207 at Two Different Application Locations for 30 Minutes With Intranasal Zolmitriptan 2.5 mg and 1 Hour Wear Time in Healthy Volunteers [NCT03708744]Phase 124 participants (Actual)Interventional2018-11-01Completed
Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches [NCT04066023]Phase 2/Phase 342 participants (Actual)Interventional2019-10-03Completed
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine [NCT03282227]Phase 3342 participants (Actual)Interventional2017-11-07Completed
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine [NCT02745392]Phase 2/Phase 3365 participants (Actual)Interventional2016-06-30Completed
A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spra [NCT00637286]Phase 4120 participants (Actual)Interventional2004-07-31Completed
A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan [NCT01086358]Phase 460 participants (Actual)Interventional2009-09-30Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents [NCT01211145]Phase 41,653 participants (Actual)Interventional2010-09-30Completed
A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura [NCT00442936]Phase 31,380 participants (Actual)Interventional2007-02-15Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in the Acute Treatment of Adult Subjects With Migraine. [NCT00617747]Phase 32,114 participants (Actual)Interventional2002-09-30Completed
A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults [NCT02609945]Phase 121 participants (Actual)Interventional2015-11-30Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study With Single-Blind, Placebo-Challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents. [NCT00617695]Phase 3247 participants (Actual)Interventional2003-09-30Completed
Behavioral Effects of Drugs (Inpatient): 42 (Cocaine and Zolmitriptan) [NCT05019430]Early Phase 120 participants (Anticipated)Interventional2021-10-15Recruiting
A Phase 1 Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder in Chronic Smokers and People With Mild or Moderate Asthma Compared to Healthy Volunteers [NCT02905227]Phase 160 participants (Actual)Interventional2016-09-30Completed
Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine Headache in Emergency Department: Randomize Controlled Trial [NCT03145467]Phase 4200 participants (Actual)Interventional2016-01-31Completed
Pharmacokinetic Model Based on Population Physiology of Oral and Intranasal Formulations of Zolmitriptan in Healthy Volunteers [NCT06074016]Phase 18 participants (Actual)Interventional2023-07-12Completed
A Randomized Open-label Four-way Crossover Study of Pharmacokinetics, Safety, and Tolerability of 3 Formulations of M207 3.8 mg on the Upper Arm for 30 Minutes With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers [NCT03978403]Phase 124 participants (Actual)Interventional2019-05-29Completed
A Randomized Open-Label Three-Way Crossover Study to Compare the Pharmacokinetics, Safety, and Tolerability of Two Lots of M207 3.8 mg (Administered as Two 1.9 mg Patches on the Upper Arm for 30 Minutes) and Intranasal Zolmitriptan 5.0 mg x 2 Doses in Hea [NCT04969497]Phase 148 participants (Actual)Interventional2021-06-24Completed
Zolmitriptan Nasal Spray VS Eletriptan in the Acute Treatment of Migraine [NCT01276977]80 participants (Actual)Interventional2008-04-30Completed
Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial [NCT03377257]Phase 471 participants (Anticipated)Interventional2018-01-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00442936 (10) [back to overview]Number of Participants With Absence of Photophobia at 2 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants With Absence of Phonophobia at 2 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants With Absence of Nausea at 2 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants Who Experience At Least One Adverse Event (AE)
NCT00442936 (10) [back to overview]Number of Participants With Sustained Pain Freedom (SPF) From 2 to 24 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants Who Discontinue Study Drug Due to an AE
NCT00442936 (10) [back to overview]Number of Participants With Total Migraine Freedom (TMF) at 2 to 24 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose
NCT00442936 (10) [back to overview]Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose
NCT01086358 (4) [back to overview]Favorable Response on Migraine-ACT
NCT01086358 (4) [back to overview]Workplace Productivity and Activity Impairment Scale (WPAI).
NCT01086358 (4) [back to overview]Lost Workplace Productivity
NCT01086358 (4) [back to overview]Lost Activity Time
NCT01211145 (6) [back to overview]Pain-free Status at 24 Hours Post-treatment
NCT01211145 (6) [back to overview]Sustained Headache Response at 2 Hours
NCT01211145 (6) [back to overview]Use of Rescue Medication During the First 24 Hours After Treatment
NCT01211145 (6) [back to overview]Headache Response at 24 Hours Post-treatment
NCT01211145 (6) [back to overview]Headache Response at 2 Hours Post-treatment
NCT01211145 (6) [back to overview]Pain-free Status at 2 Hours Post-treatment
NCT02745392 (2) [back to overview]Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)
NCT02745392 (2) [back to overview]Proportion of Subjects With Pain Freedom
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Photophobia Freedom Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Pain Relief Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Phonophobia Freedom Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Pain Freedom Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Nausea Freedom Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Percentage of Migraine Attacks for Which Most Bothersome Symptom Freedom Was Achieved at 2 Hours Post-dose
NCT03282227 (7) [back to overview]Number of Subjects With Any Treatment-emergent Adverse Events (TEAE) Over 12 Months
NCT03708744 (3) [back to overview]Adverse Events
NCT03708744 (3) [back to overview]Cmax
NCT03708744 (3) [back to overview]t(1/2)
NCT03978403 (3) [back to overview]Adverse Events
NCT03978403 (3) [back to overview]Cmax
NCT03978403 (3) [back to overview]Tmax
NCT04066023 (11) [back to overview]Percentage of Subjects Able to Perform Their Usual Daily Activities as Assessed by the Subject
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Pain Freedom
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Sustained Pain Freedom
NCT04066023 (11) [back to overview]Percentage of Subjects Who Achieve Sustained Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects Who Achieve Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Pain Freedom
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Sustained Pain Relief
NCT04066023 (11) [back to overview]Percentage of Subjects That Achieve Sustained Pain Relief

Number of Participants With Absence of Photophobia at 2 Hours Post-Dose

Participants were asked if they experienced any sensitivity to light. The number of participants who experienced no photophobia (sensitivity to light) at 2 hours post-dose was determined. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg143
Telcagepant 300 mg169
Zolmitriptan 5 mg163
Placebo92

[back to top]

Number of Participants With Absence of Phonophobia at 2 Hours Post-Dose

Participants were asked if they experienced any sensitivity to sound. The number of participants who experienced no phonophobia (sensitivity to sound) at 2 hours post-dose was determined. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg170
Telcagepant 300 mg193
Zolmitriptan 5 mg180
Placebo120

[back to top]

Number of Participants With Absence of Nausea at 2 Hours Post-Dose

Participants were asked if they experienced any nausea. The number of participants who experienced no nausea at 2 hours post-dose was determined. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg212
Telcagepant 300 mg218
Zolmitriptan 5 mg232
Placebo179

[back to top]

Number of Participants Who Experience At Least One Adverse Event (AE)

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 14 days after last dose study drug. Participants who took both active and placebo study drug were counted in the active group. (NCT00442936)
Timeframe: Up to 14 days after last dose of study drug

InterventionParticipants (Number)
Telcagepant 150 mg105
Telcagepant 300 mg131
Zolmitriptan 5 mg175
Placebo112

[back to top]

Number of Participants With Sustained Pain Freedom (SPF) From 2 to 24 Hours Post-Dose

SPF is defined as PF at 2 hours post-dose with no return of mild/moderate/severe headache through 24 hours post-dose, and with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose. (NCT00442936)
Timeframe: 2 to 24 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg34
Telcagepant 300 mg66
Zolmitriptan 5 mg59
Placebo14

[back to top]

Number of Participants Who Discontinue Study Drug Due to an AE

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants who took both active and placebo study drug were counted in the active group. (NCT00442936)
Timeframe: Up to 48 hours after first dose of study drug

InterventionParticipants (Number)
Telcagepant 150 mg0
Telcagepant 300 mg0
Zolmitriptan 5 mg0
Placebo0

[back to top]

Number of Participants With Total Migraine Freedom (TMF) at 2 to 24 Hours Post-Dose

TMF at 2 to 24 hours post-dose is defined as TMF at 2 hours post-dose with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose, no return of mild/moderate/severe headache within 24 hours and no presence of phonophobia, photophobia, nausea or vomiting within 24 hours post-dose. (NCT00442936)
Timeframe: 2 to 24 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg26
Telcagepant 300 mg57
Zolmitriptan 5 mg51
Placebo13

[back to top]

Number of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose

TMF at 2 hours post-dose is defined as PF at 2 hours post-dose without any of the following migraine-related symptoms: phonophobia, photophobia, nausea or vomiting at 2 hours post-dose. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg43
Telcagepant 300 mg76
Zolmitriptan 5 mg87
Placebo27

[back to top]

Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose

Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PR at 2 hours post-dose is defined as a shift from a moderate or severe migraine headache (Grade 2 or 3) at baseline to mild or no pain (Grade 1 or 0) at 2 hours post-dose. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg157
Telcagepant 300 mg183
Zolmitriptan 5 mg185
Placebo88

[back to top]

Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose

Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at baseline to no pain (Grade 0) at 2 hours post-dose. (NCT00442936)
Timeframe: 2 hours post-dose

InterventionParticipants (Number)
Telcagepant 150 mg56
Telcagepant 300 mg89
Zolmitriptan 5 mg101
Placebo29

[back to top]

Favorable Response on Migraine-ACT

The Migraine-ACT is a 4-item scale with yes/no responses. A score of 3 or more is considered favorable. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The Migraine-ACT is reported as a binary measure (3 or more positive responses). The outcome presented included the percentage with a score of 3 or more, and the Odds ratio comparing the two treatments. (NCT01086358)
Timeframe: 6 months

Interventionpercentage of favorable responses (Mean)
Arm 1 - Triptan46
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm71

[back to top]

Workplace Productivity and Activity Impairment Scale (WPAI).

The primary outcome measure was lost productivity (workplace productivity + non-workplace activity time) as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months

Interventionhours (Mean)
Arm 1 - Triptan4.15
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm2.44

[back to top]

Lost Workplace Productivity

This outcome measure was lost workplace productivity as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 months

Interventionhours (Mean)
Arm 1 - Triptan2.25
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm1.23

[back to top]

Lost Activity Time

This outcome measure was lost activity time as measured by a variant of the Work Productivity and Activity Impairment Scale (WPAI) at 6 months.The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The primary efficacy dataset included the 37 patients that completed both phases of the study and uses the last observed headache. The unit of analysis is hours lost. The higher the score the greater impact on productivity. The range depends on the length of the attack, but in the sample among all observed attacks, lost work productivity ranged from 0-10.5 hours, while lost non-workplace activity time ranged from 0 to 8.95 hours. The total lost productivity is the sum of lost work productivity and lost non-workplace activity time. (NCT01086358)
Timeframe: 6 Months

Interventionhours (Mean)
Arm 1 - Triptan1.89
Arm 2 - Sumatriptan/Naproxen Sodium (Treximet) Arm1.22

[back to top]

Pain-free Status at 24 Hours Post-treatment

(NCT01211145)
Timeframe: 24 hours post-treatment

,,,
InterventionParticipants (Number)
YesNo
Placebo15596
ZOMIG 0.5 mg5932
ZOMIG 2.5 mg6020
ZOMIG 5 mg15572

[back to top]

Sustained Headache Response at 2 Hours

Sustained headache response at 2 hours is a binary response variable derived from the headache intensities recorded in the patient diary. Sustained headache response is defined as a reduction in migraine headache pain intensity from severe or moderate to mild or none a 1 hr. which is then maintained (without a return to moderate or severe pain) at 2 hrs. with no use of rescue medication prior to the 2 hr. assessment. (NCT01211145)
Timeframe: Up to 2 hours post-treatment

,,,
InterventionParticipants (Number)
YesNo
Placebo59192
ZOMIG 0.5 mg2764
ZOMIG 2.5 mg2754
ZOMIG 5 mg66158

[back to top]

Use of Rescue Medication During the First 24 Hours After Treatment

(NCT01211145)
Timeframe: 24 hours post-treatment.

,,,
InterventionParticipants (Number)
YesNo
Placebo80173
ZOMIG 0.5 mg2269
ZOMIG 2.5 mg1863
ZOMIG 5 mg47184

[back to top]

Headache Response at 24 Hours Post-treatment

Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment. (NCT01211145)
Timeframe: 24 hours post-treatment

,,,
InterventionParticipants (Number)
YesNo
Placebo17081
ZOMIG 0.5 mg6328
ZOMIG 2.5 mg6119
ZOMIG 5 mg16859

[back to top]

Headache Response at 2 Hours Post-treatment

Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment. (NCT01211145)
Timeframe: 2 hours post-treatment

,,,
InterventionParticipants (Number)
YesNo
Placebo99154
ZOMIG 0.5 mg4051
ZOMIG 2.5 mg4338
ZOMIG 5 mg116113

[back to top]

Pain-free Status at 2 Hours Post-treatment

(NCT01211145)
Timeframe: 2 hours post-treatment.

,,,
InterventionParticipants (Number)
YesNo
Placebo42211
ZOMIG 0.5 mg2071
ZOMIG 2.5 mg2061
ZOMIG 5 mg68161

[back to top]

Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)

The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success. (NCT02745392)
Timeframe: 2 hours

InterventionParticipants (Count of Participants)
Placebo33
ZP-Zolmitriptan 1 mg45
ZP-Zolmitriptan 1.9 mg44
ZP-Zolmitriptan 3.8 mg56

[back to top]

Proportion of Subjects With Pain Freedom

Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours. (NCT02745392)
Timeframe: 2 hours

InterventionParticipants (Count of Participants)
Placebo11
ZP-Zolmitriptan 1 mg24
ZP-Zolmitriptan 1.9 mg23
ZP-Zolmitriptan 3.8 mg34

[back to top]

Percentage of Migraine Attacks for Which Photophobia Freedom Was Achieved at 2 Hours Post-dose

Percentage of migraine attacks for which photophobia freedom defined as an absence of photophobia without the use of rescue medication was achieved at 2 hours post-dose. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hour data (Count of Units)
M207 Microneedle System 3.8 mg3410

[back to top]

Percentage of Migraine Attacks for Which Pain Relief Was Achieved at 2 Hours Post-dose

Percentage of migraine attacks for which pain relief defined as an improvement of pain severity (1) to mild (Grade 1) or none (Grade 0) from moderate (Grade 2) or severe (Grade 3) at baseline, or (2) an improvement of pain severity to none (Grade 0) from mild (Grade 1) at baseline, without rescue medication was achieved. Pain severity scale has grades: 0: None, 1: Mild, 2: Moderate, 3: Severe, where lower values represent a better outcome. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hr data (Count of Units)
M207 Microneedle System 3.8 mg4552

[back to top]

Percentage of Migraine Attacks for Which Phonophobia Freedom Was Achieved at 2 Hours Post-dose

Percentage of migraine attacks for which phonophobia freedom defined as an absence of phonophobia without the use of rescue medication was achieved at 2 hours post-dose. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hour data (Count of Units)
M207 Microneedle System 3.8 mg3563

[back to top]

Percentage of Migraine Attacks for Which Pain Freedom Was Achieved at 2 Hours Post-dose

Percentage of migraine attacks for which pain freedom defined as a pain level of 'None' (Grade 0 on pain severity scale where 0: None, 1: Mild, 2: Moderate, 3: Severe, and lower values represent a better outcome) was achieved at 2 hours post-dose without the use of rescue medication. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hour data (Count of Units)
M207 Microneedle System 3.8 mg2477

[back to top]

Percentage of Migraine Attacks for Which Nausea Freedom Was Achieved at 2 Hours Post-dose

Percentage of subjects for which nausea freedom defined as absence of nausea and/or vomiting without the use of rescue medication was achieved at 2 hours post-dose. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hr data (Count of Units)
M207 Microneedle System 3.8 mg4628

[back to top]

Percentage of Migraine Attacks for Which Most Bothersome Symptom Freedom Was Achieved at 2 Hours Post-dose

Percentage of migraine attacks for which freedom from most bothersome symptom other than pain defined as an absence of the most bothersome symptom was achieved at 2 hours post-dose without the use of rescue medication. This was an open-label study with no control group. No statistical analyses were performed. (NCT03282227)
Timeframe: 2 hours for each Migraine, up to 12 months for each subject

InterventionQualifying migraines with 2 hr data (Count of Units)
M207 Microneedle System 3.8 mg3315

[back to top]

Number of Subjects With Any Treatment-emergent Adverse Events (TEAE) Over 12 Months

Number and % of subjects in safety population with any treatment-emergent adverse event(s) during the study. TEAE is defined as any new adverse event (AE) that started after first patch application. This was an open-label study with no control group. No statistical analyses were performed. Application site skin reactions including erythema, swelling, haemorrhage, bruise, pain, and pruritus were collected systematically via subject e-diary and/or investigator skin assessment at study visits. All other AEs were spontaneously reported by subject or observed upon examination. (NCT03282227)
Timeframe: 0 to 12 months

InterventionParticipants (Count of Participants)
M207 Microneedle System 3.8 mg323

[back to top]

Adverse Events

number of subjects that experienced at least one adverse event (NCT03708744)
Timeframe: 24 hours

InterventionParticipants (Number)
Treatment A4
Treatment B3
Treatment C1
Treatment D1

[back to top]

Cmax

maximum observed plasma concentration (NCT03708744)
Timeframe: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose

Interventionpg/mL (Geometric Mean)
Treatment A9180.9
Treatment B5925.9
Treatment C15224.3
Treatment D3758.3

[back to top]

t(1/2)

apparent half-life (NCT03708744)
Timeframe: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes, 2, 4, 8, 12, 24 hours post-dose

Interventionhours (Mean)
Treatment A2.692
Treatment B2.975
Treatment C2.959
Treatment D4.545

[back to top]

Adverse Events

Subjects with treatment emergent adverse events (NCT03978403)
Timeframe: 48 hours

InterventionParticipants (Count of Participants)
M207 3.8 mg (Sled)18
M207 3.8 mg (MACAP)15
M207 e.8 mg (MiniMac)13
Zolmitriptan 2.5 mg (Intranasal)4

[back to top]

Cmax

maximum observed plasma concentration (NCT03978403)
Timeframe: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose

Interventionpg/mL (Geometric Mean)
M207 3.8 mg (Sled)11670
M207 3.8 mg (MACAP)9861
M207 3.8 mg (MiniMac)11680
Zolmitriptan 2.5 mg (Intranasal)3705

[back to top]

Tmax

Time to maximum concentration (NCT03978403)
Timeframe: pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 90 minutes; 2, 4 , 8, 12, and 24 hours post-dose

Interventionhour (Median)
M207 3.8 mg (Sled)0.529
M207 3.8 mg (MACAP)0.577
M207 3.8 mg (MiniMac)0.575
Zolmitriptan 2.5 mg (Intranasal)2.000

[back to top]

Percentage of Subjects Able to Perform Their Usual Daily Activities as Assessed by the Subject

"Whether or not subjects were able to perform their usual daily activities was assessed by subject responses (Yes or No) in the electronic diary (eDiary) to the question, Do you feel able to perform your usual daily activities? If a subject responded Yes but had used a rescue medication, the subject was considered as not being able to perform the usual daily activities." (NCT04066023)
Timeframe: within 20 minutes

InterventionParticipants (Count of Participants)
Placebo2
C213 1.9 mg5
C213 3.8mg4

[back to top]

Percentage of Subjects That Achieve Pain Freedom

Pain freedom is defined by a decrease in pain from severe to none without the use of acute rescue medication. (NCT04066023)
Timeframe: 10 minutes

InterventionParticipants (Count of Participants)
Placebo0
C213 1.9 mg1
C213 3.8mg1

[back to top]

Percentage of Subjects That Achieve Pain Relief

Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication (NCT04066023)
Timeframe: 10 minutes

InterventionParticipants (Count of Participants)
Placebo2
C213 1.9 mg3
C213 3.8mg3

[back to top]

Percentage of Subjects That Achieve Pain Relief

Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. (NCT04066023)
Timeframe: 20 minutes

InterventionParticipants (Count of Participants)
Placebo4
C213 1.9 mg5
C213 3.8mg4

[back to top]

Percentage of Subjects That Achieve Pain Relief

Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. (NCT04066023)
Timeframe: 5 minutes

InterventionParticipants (Count of Participants)
Placebo0
C213 1.9 mg2
C213 3.8mg1

[back to top]

Percentage of Subjects That Achieve Sustained Pain Freedom

Sustained pain freedom requires a pain rating of none at each timepoint within the time frame without the use of acute rescue medication. (NCT04066023)
Timeframe: 15 to 60 minutes

InterventionParticipants (Count of Participants)
Placebo1
C213 1.9 mg2
C213 3.8mg2

[back to top]

Percentage of Subjects Who Achieve Sustained Pain Relief

Sustained pain relief requires a pain rating of mild or none at each timepoint from 15 minutes to 60 minutes without the use of acute rescue medication. (NCT04066023)
Timeframe: 15 minutes to 60 minutes

InterventionParticipants (Count of Participants)
Placebo3
C213 1.9 mg4
C213 3.8mg5

[back to top]

Percentage of Subjects Who Achieve Pain Relief

Pain relief is defined by a decrease in pain from severe to mild or none without the use of acute rescue medication. (NCT04066023)
Timeframe: 15 minutes

InterventionParticipants (Count of Participants)
Placebo3
C213 1.9 mg5
C213 3.8mg5

[back to top]

Percentage of Subjects That Achieve Pain Freedom

Pain freedom is defined by a decrease in pain from severe to none without the use of acute rescue medication. (NCT04066023)
Timeframe: 20 minutes

InterventionParticipants (Count of Participants)
Placebo2
C213 1.9 mg3
C213 3.8mg3

[back to top]

Percentage of Subjects That Achieve Sustained Pain Relief

Sustained pain relief requires a pain rating of mild or none at each timepoint within the time frame without the use of acute rescue medication. (NCT04066023)
Timeframe: 5 minutes to 60 minutes

InterventionParticipants (Count of Participants)
Placebo0
C213 1.9 mg2
C213 3.8mg1

[back to top]

Percentage of Subjects That Achieve Sustained Pain Relief

Sustained pain relief requires a pain rating of mild or none at each timepoint within the time frame without the use of acute rescue medication. (NCT04066023)
Timeframe: 10 minutes to 60 minutes

InterventionParticipants (Count of Participants)
Placebo2
C213 1.9 mg3
C213 3.8mg3

[back to top]